Literature DB >> 2010626

Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages.

P Ashorn1, G Englund, M A Martin, B Moss, E A Berger.   

Abstract

CD4(178)-PE40 is a recombinant protein consisting of a portion of human CD4 linked to active domains of Pseudomonas aeruginosa exotoxin A. In previous experiments with human T cell lines, the hybrid toxin was found to selectively kill cells infected with human immunodeficiency virus type 1 (HIV-1), and to inhibit HIV-1 spread in mixtures of infected and uninfected cells. CD4(178)-PE40 inhibits HIV-1 spread in cultured primary human lymphocytes. Moreover, the hybrid toxin selectively kills HIV-1 chronically infected monocyte/macrophage cell lines and inhibits HIV-1 spread in primary macrophage cultures. Control experiments indicate that the protective effects of CD4(178)-PE40 against HIV-1 spread are due to selective killing of the infected cells rather than simply to neutralization by the CD4 moiety. Thus, for the major cell types susceptible to HIV infection in vivo, surface envelope glycoprotein is expressed at sufficient levels to enable binding and internalization of CD4(178)-PE40 and consequent selective cell killing.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2010626     DOI: 10.1093/infdis/163.4.703

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.

Authors:  Deboeeta Chatterjee; Bala Chandran; Edward A Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

Authors:  Edward A Berger; Ira Pastan
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

Review 4.  Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART.

Authors:  E A Berger; B Moss; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

5.  Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates.

Authors:  Ryan B Craig; Christopher M Summa; Miriam Corti; Seth H Pincus
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.